Status:
RECRUITING
Clinical, Laboratory and Ultrasound Stratification of Patients With Juvenile Idiopathic Arthritis
Lead Sponsor:
IRCCS Burlo Garofolo
Conditions:
Juvenile Idiopathic Arthritis
Eligibility:
All Genders
Up to 18 years
Brief Summary
Juvenile Idiopathic Arthritis (JIA), the most common rheumatologic chronic disease in children, is defined as arthritis persisting for at least 6 weeks with no known cause in a patient under the age o...
Eligibility Criteria
Inclusion
- Subjects under the age of 18 years
- Arthritis persisting for at least 6 weeks with no known cause
Exclusion
- No consent from the patients' guardians
- Patients with Systemic onset Juvenile Idiopathic Arthritis
- Patients who developed arthritis on a pre-existing inflammatory disorder such as Inflammatory Bowel Disease, and had received previous treatments
Key Trial Info
Start Date :
January 10 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 15 2026
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06007456
Start Date
January 10 2022
End Date
March 15 2026
Last Update
June 14 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS Burlo Garofolo
Trieste, Italy, 34137
2
(Department of Medical and Biological Sciences, Rheumatology Clinic, University of Udine
Udine, Italy